{"content":"<li class=\"n-box-item date-title\" data-end=\"1503374399\" data-start=\"1503288000\" data-txt=\"Monday, December 23, 2019\">Monday, August 21, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3290824\" data-ts=\"1503351422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDSN\" target=\"_blank\">NDSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290824-nordsonminus-11-on-below-consensus-fq4-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordson -11% on below consensus FQ4 outlook</a></h4><ul>     <li>Nordson (NASDAQ:<a href='https://seekingalpha.com/symbol/NDSN' title='Nordson Corporation'>NDSN</a>) <font color='red'>-10.8%</font>&nbsp;AH after reporting better than expected <a href=\"https://seekingalpha.com/news/3290796-nordson-beats-0_11-beats-revenue\" target=\"_blank\">FQ3 earnings</a> but guiding FQ4 earnings and revenues below analyst consensus.</li>     <li>NDSN sees Q4 EPS of  $1.18-$1.32 vs. $1.52 analyst consensus estimate on a 4%-8% Y/Y revenue gain, which translates to $530M-$550M vs. $565M consensus; organic volume is forecast to fall 3%-7%, with operating  margin expected at ~21% at the midpoint.</li>     <li>NDSN says order rates for the 12 weeks ending Aug. 13 fell 2% Y/Y; backlog for FQ3 was ~$372M, up 10% from the year-ago period, with 13% growth due to acquisitions offset by a 3% decline in organic  growth.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290824\" data-linked=\"Nordson -11% on below consensus FQ4 outlook\" data-tweet=\"$NDSN - Nordson -11% on below consensus FQ4 outlook https://seekingalpha.com/news/3290824-nordsonminus-11-on-below-consensus-fq4-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3290824-nordsonminus-11-on-below-consensus-fq4-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290822\" data-ts=\"1503351229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290822-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/RT' title='Ruby Tuesday, Inc.'>RT</a> <font color='green'>+11.0%</font>. <a href='https://seekingalpha.com/symbol/JASO' title='JA Solar Holdings, Co., Ltd.'>JASO</a> <font color='green'>+3.4%</font>. <a href='https://seekingalpha.com/symbol/MATR' title='Mattersight Corporation'>MATR</a> <font color='green'>+2.4%</font>. <a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='green'>+2.0%</font>. <a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a> <font color='green'>+1.8%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/NDSN' title='Nordson Corporation'>NDSN</a> <font color='red'>-9.9%</font>. <a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a> <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group'>ZAYO</a> <font color='red'>-3.4%</font>. <a href='https://seekingalpha.com/symbol/TEDU' title='Tarena International, Inc.'>TEDU</a> <font color='red'>-3.3%</font>. <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='red'>-2.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290822\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$RT $JASO $MATR - After Hours Gainers / Losers https://seekingalpha.com/news/3290822-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3290822-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290821\" data-ts=\"1503351092\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPCO\" target=\"_blank\">TPCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290821-tronc-replaces-leadership-los-angeles-times\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tronc replaces leadership at Los Angeles Times</a></h4><ul>   <li>Tronc (<a href=\"http://seekingalpha.com/symbol/TRNC\" target=\"_blank\">TRNC</a> <font color='green'>+4.1%</font>) has instituted a shake-up at the <i>Los Angeles Times,</i> one of its nine newspapers, by <a href=\"http://www.latimes.com/business/hollywood/la-fi-ct-los-angeles-times-20170821-story.html\" target=\"_blank\">firing leadership and installing new executives</a>.</li>    <li>The company named former interim Yahoo chief Ross Levinsohn publisher and CEO at the paper, and put veteran Chicago Sun-Times Publisher/Editor Jim Kirk in charge as interim editor.</li>    <li>The paper's existing editor and publisher, Davan Maharaj, was terminated along with Managing Editor Marc Duvoisin, Deputy Managing Editor for Digital Megan Garvey and Assistant Managing Editor of Investigations Matt Doig.</li>    <li>Tronc chief Justin Dearborn says the plans are to invest more heavily in Washington news and improve coverage of culture and sports. &ldquo;Ross isn&rsquo;t coming in to manage further downsizing,&rdquo; Dearborn says; \"we have more to offer.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290821\" data-linked=\"Tronc replaces leadership at Los Angeles Times\" data-tweet=\"$TPCO - Tronc replaces leadership at Los Angeles Times https://seekingalpha.com/news/3290821-tronc-replaces-leadership-los-angeles-times?source=tweet\" data-url=\"https://seekingalpha.com/news/3290821-tronc-replaces-leadership-los-angeles-times\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290815\" data-ts=\"1503349087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FN\" target=\"_blank\">FN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290815-fabrinetminus-3_9-current-quarter-guidance-falls-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fabrinet -3.9% as current-quarter guidance falls short</a></h4><ul>   <li>Fabrinet (<a href=\"http://seekingalpha.com/symbol/FN\" target=\"_blank\">FN</a> <font color='red'>-0.7%</font>) is <font color='red'>off 3.9%</font> after hours after <a href=\"https://seekingalpha.com/news/3290782-fabrinet-beats-0_03-beats-revenue\" target=\"_blank\">Q4 earnings</a> where it beat expectations but guided low for its current first quarter.</li>    <li>Revenue growth was solid at 34%, and the company posted its 12th straight quarter of Y/Y revenue gains.</li>    <li>Non-GAAP net income rose 46% Y/Y to $32.8M.</li>    <li>The company also approved share repurchases in the amount of $30M.</li>    <li>For the current quarter, it's guiding to revenues of $356M-$360M (below consensus for $375.6M), and GAAP EPS of $0.60-$0.62 and non-GAAP EPS of $0.78-$0.80 (light of consensus for $0.87).</li>    <li><a href=\"http://investor.fabrinet.com\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16920283-fabrinet-announces-fourth-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3290815\" data-linked=\"Fabrinet -3.9% as current-quarter guidance falls short\" data-tweet=\"$FN - Fabrinet -3.9% as current-quarter guidance falls short https://seekingalpha.com/news/3290815-fabrinetminus-3_9-current-quarter-guidance-falls-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3290815-fabrinetminus-3_9-current-quarter-guidance-falls-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290811\" data-ts=\"1503348543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAYO\" target=\"_blank\">ZAYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290811-zayo-groupminus-5_7-after-q4-profits-revenues-disappoint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zayo Group -5.7% after Q4 profits, revenues disappoint</a></h4><ul>   <li>Zayo Group (NYSE:<a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group'>ZAYO</a>) has <font color='red'>slipped 5.7%</font> after hours after posting <a href=\"https://seekingalpha.com/news/3290777-zayo-misses-0_06-misses-revenue\" target=\"_blank\">fiscal Q4 earnings</a> that missed on top and bottom lines.</li>    <li>Revenue grew 26% and the company swung to a net profit of $23.2M, however, from a year-ago loss of $30.9M.</li>    <li>EBITDA was $310.8M, missing an expected $314.3M.</li>    <li>Bookings came to $7.5M, with gross installs of $7.3M, net installs of $1.4M and churn of 1.2%.</li>    <li>Revenue breakout: Communications Infrastructure, $509.1M; Allstream, $128.9M.</li>    <li>Adjusted unlevered free cash flow came to $117.2M. As of June 30, there was $220.7M in cash and $442.2M available under its revolving credit.</li>    <li><a href=\"http://services.choruscall.com/links/zayo1708212s01HOaV.html\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16920268-zayo-group-holdings-inc-reports-financial-results-fourth-fiscal-quarter-ended-june-30-2017\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3290811\" data-linked=\"Zayo Group -5.7% after Q4 profits, revenues disappoint\" data-tweet=\"$ZAYO - Zayo Group -5.7% after Q4 profits, revenues disappoint https://seekingalpha.com/news/3290811-zayo-groupminus-5_7-after-q4-profits-revenues-disappoint?source=tweet\" data-url=\"https://seekingalpha.com/news/3290811-zayo-groupminus-5_7-after-q4-profits-revenues-disappoint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290809\" data-ts=\"1503348444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290809-ruby-tuesday-higher-after-improved-margin-rate-forecast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ruby Tuesday higher after improved margin rate forecast</a></h4><ul> <li>Comparable sales fell off 1.6% at Ruby Tuesday RT in <a href=\"https://seekingalpha.com/pr/16920291-ruby-tuesday-inc-reports-fourth-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">FQ4</a>. Total sales were down 8.8% as a reduction in stores factored in.</li> <li>Restaurant level margin fell 40 bps to 18.3% of sales. Cost of goods sold was flat compared to a year ago at 27.6% of sales.</li> <li>Looking ahead, Ruby Tuesday says it expects to achieve year-over-year improvement in restaurant level margins and EBITDA in FY18.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290783-ruby-tuesday-reports-q4-results\" target=\"_blank\">Ruby Tuesday reports Q4 results</a> (Aug. 21)</li> <li>Shares of Ruby Tuesday are <font color='green'>up 5.98%</font> in AH trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290809\" data-linked=\"Ruby Tuesday higher after improved margin rate forecast\" data-tweet=\"Ruby Tuesday higher after improved margin rate forecast https://seekingalpha.com/news/3290809-ruby-tuesday-higher-after-improved-margin-rate-forecast?source=tweet\" data-url=\"https://seekingalpha.com/news/3290809-ruby-tuesday-higher-after-improved-margin-rate-forecast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290772\" data-ts=\"1503345424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FQVLF\" target=\"_blank\">FQVLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290772-full-power-supply-restored-to-first-quantum-mines-in-zambia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Full power supply restored to First Quantum mines in Zambia</a></h4><ul>     <li>First Quantum Minerals (<a href='https://seekingalpha.com/symbol/FQVLF' title='First Quantum Minerals Ltd.'>OTCPK:FQVLF</a> <font color='green'>+5%</font>) surges after Zambia <a href=\"http://www.miningweekly.com/article/zambia-restores-full-power-supply-to-first-quantum-mines-2017-08-21\" target=\"_blank\">restored full electricity supply</a> to two of its copper mines over the weekend, after reducing them last week over a pricing dispute.</li><li>Zambia's state power company had reduced electricity supply to the two mines because the mining firm had failed to pay a new flat electricity tariff, but the government said talks with First Quantum determined that the company would pay the new tariff structure beginning January of this year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290772\" data-linked=\"Full power supply restored to First Quantum mines in Zambia\" data-tweet=\"$FQVLF - Full power supply restored to First Quantum mines in Zambia https://seekingalpha.com/news/3290772-full-power-supply-restored-to-first-quantum-mines-in-zambia?source=tweet\" data-url=\"https://seekingalpha.com/news/3290772-full-power-supply-restored-to-first-quantum-mines-in-zambia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290761\" data-ts=\"1503344205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETS\" target=\"_blank\">PETS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290761-petmed-express-completes-round-trip-from-fq1-up-move-shares-down-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PetMed Express completes round trip from FQ1 up move; shares down 6%</a></h4><ul><li>PetMed Express (<a href='https://seekingalpha.com/symbol/PETS' title='PetMed Express, Inc.'>PETS</a> <font color='red'>-5.7%</font>) slumps on 50% higher volume completing a round trip since the stock broke out of consolidation on July 24 after its fiscal Q1 beat. Shares have lost almost 18% of their value since touching $50.90 on July 27.</li><li>The consensus sell-side rating is Hold with an average price target of $40.75 (3% downside risk).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280497-petmed-express-beats-0_07-beats-revenue\" target=\"_blank\">PetMed Express beats by $0.07, beats on revenue</a> (July 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280509-petmed-express-q1-revenues-10-percent-eps-41-percent\" target=\"_blank\">PetMed Express Q1 revenues up 10%; EPS up 41%</a> (July 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3290761\" data-linked=\"PetMed Express completes round trip from FQ1 up move; shares down 6%\" data-tweet=\"$PETS - PetMed Express completes round trip from FQ1 up move; shares down 6% https://seekingalpha.com/news/3290761-petmed-express-completes-round-trip-from-fq1-up-move-shares-down-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3290761-petmed-express-completes-round-trip-from-fq1-up-move-shares-down-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290762\" data-ts=\"1503343833\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSLR\" target=\"_blank\">FSLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290762-solar-company-stocks-sink-amid-eclipse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Solar company stocks sink amid eclipse</a></h4><ul><li>Solar stocks are broadly lower with no clear explanation, as today's solar eclipse across the U.S. puts the <a href=\"https://www.bloomberg.com/news/articles/2017-08-21/historic-eclipse-will-test-america-s-grid-as-solar-waxes-wanes\" target=\"_blank\">solar grid under the microscope</a>.</li><li>First Solar (<a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a> <font color='red'>-4.4%</font>) says it spent a year planning for the eclipse, including holding dress  rehearsals, but operations manager William Byrd warned earlier of \"unexpected things... it&rsquo;s a pretty  big megawatt drop.\"</li><li>Also: <a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a> <font color='red'>-4.7%</font>, <a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='red'>-8.6%</font>, <a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='red'>-8.8%</font>, <a href='https://seekingalpha.com/symbol/RUN' title='Sunrun'>RUN</a> <font color='red'>-1.9%</font>, <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='red'>-2.6%</font>, <a href='https://seekingalpha.com/symbol/SOL' title='ReneSola Ltd.'>SOL</a> <font color='red'>-3%</font>, <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-0.8%</font>, <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='red'>-2.4%</font>, <a href='https://seekingalpha.com/symbol/SEDG' title='SolarEdge Technologies'>SEDG</a> <font color='red'>-2.5%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/TAN' title='Invesco Solar Portfolio ETF'>TAN</a>, <a href='https://seekingalpha.com/symbol/KWT' title='VanEck Vectors Solar Energy ETF'>KWT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3290762\" data-linked=\"Solar company stocks sink amid eclipse\" data-tweet=\"$FSLR $FSLR $SPWR - Solar company stocks sink amid eclipse https://seekingalpha.com/news/3290762-solar-company-stocks-sink-amid-eclipse?source=tweet\" data-url=\"https://seekingalpha.com/news/3290762-solar-company-stocks-sink-amid-eclipse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290754\" data-ts=\"1503341793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290754-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/WUBA' title='58.com Inc.'>WUBA</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/IGLD' title='Internet Gold Golden Lines Ltd.'>IGLD</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/XPLR' title='Xplore Technologies Corp.'>XPLR</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/NTL' title='Nortel Inversora S A'>NTL</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SMSI' title='Smith Micro Software, Inc.'>SMSI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290754\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$VERI $WUBA $IGLD - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3290754-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3290754-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290748\" data-ts=\"1503338486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290748-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ECT' title='ECA Marcellus Trust I'>ECT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/AROC' title='Archrock Inc.'>AROC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/ICD' title='Independence Contract Drilling'>ICD</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290748\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$XCO $ZN $SND - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3290748-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3290748-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290742\" data-ts=\"1503335056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290742-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/PW' title='Power REIT'>PW</a> <font color='green'>+11%</font>.<a href='https://seekingalpha.com/symbol/HBMD' title='Howard Bancorp Inc.'>HBMD</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-12%</font>. RAS <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management'>MDLY</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290742\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$RTNB $PW $HBMD - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3290742-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3290742-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290734\" data-ts=\"1503333981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290734-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+42%</font>. <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/XPLR' title='Xplore Technologies Corp.'>XPLR</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/WUBA' title='58.com Inc.'>WUBA</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/NC' title='NACCO Industries Inc.'>NC</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/PW' title='Power REIT'>PW</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> CRME <font color='red'>-37%</font>. <a href='https://seekingalpha.com/symbol/NAP' title='Navios Maritime Midstream Partners LP'>NAP</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='red'>-11%</font>. EBIO <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/TGLS' title='Tecnoglass Inc.'>TGLS</a> <font color='red'>-11%</font>. LTEA <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CHKE' title='Cherokee Inc.'>CHKE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290734\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$VERI $RTNB $XPLR - Midday Gainers / Losers https://seekingalpha.com/news/3290734-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3290734-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290729\" data-ts=\"1503333282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYH\" target=\"_blank\">CYH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290729-activist-investor-seeks-ouster-of-ceo-community-health-systems-shares-ahead-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Activist investor seeks ouster of CEO at Community Health Systems, shares ahead 11%</a></h4><ul><li>Institutional investor ASL Strategic Value Fund has <a href=\"http://markets.businessinsider.com/news/stocks/r-brief-asl-strategic-fund-sends-letter-to-community-health-systems-board-2017-8-1002272783\" target=\"_blank\">sent a letter</a> to the board of Community Health Systems (<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='green'>+10.5%</font>) seeing a replacement for CEO Wayne Smith saying \"it is time\" for new leadership.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290729\" data-linked=\"Activist investor seeks ouster of CEO at Community Health Systems, shares ahead 11%\" data-tweet=\"$CYH - Activist investor seeks ouster of CEO at Community Health Systems, shares ahead 11% https://seekingalpha.com/news/3290729-activist-investor-seeks-ouster-of-ceo-community-health-systems-shares-ahead-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3290729-activist-investor-seeks-ouster-of-ceo-community-health-systems-shares-ahead-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290724\" data-ts=\"1503332680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSIQ\" target=\"_blank\">CSIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290724-canadian-solar-downgraded-barclays-on-multiple-near-term-risks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Solar downgraded at Barclays on multiple near-term risks</a></h4><ul>     <li>Canadian Solar (<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='red'>-7%</font>) is <a href=\"https://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Canadian+Solar+%28CSIQ%29+to+Underweight/13222054.html\" target=\"_blank\">downgraded</a> to Underweight from Equal Weight with a $14 price target at Barclays, which sees multiple near-term risks from the possible delay and/or weak pricing of project sales, soft investor demand for a J-REIT listing for its Japan assets in H2, and the Sept. 22 injury vote in the U.S. ITC 201 trade case.</li>     <li>Project sale timing continues to be pushed back, the firm says, with expected 2017 sales already potentially delayed into 2018 and likely driving a 2017 revenue guidance miss.</li>     <li>Barclays continues to see downward price risk potential for CSIQ to realize the full expected  $1.8B of market value given the pressure on solar project values in the  U.S. (60% of the company's portfolio); while CSIQ expects a J-REIT listing in H2, the J-REIT market continues to suffer from low liquidity, the firm adds.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290724\" data-linked=\"Canadian Solar downgraded at Barclays on multiple near-term risks\" data-tweet=\"$CSIQ - Canadian Solar downgraded at Barclays on multiple near-term risks https://seekingalpha.com/news/3290724-canadian-solar-downgraded-barclays-on-multiple-near-term-risks?source=tweet\" data-url=\"https://seekingalpha.com/news/3290724-canadian-solar-downgraded-barclays-on-multiple-near-term-risks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290721\" data-ts=\"1503331989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIDU\" target=\"_blank\">BIDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290721-wsj-baidu-will-sell-takeout-delivery-unit-this-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Baidu will sell takeout delivery unit this week</a></h4><ul><li>        Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) will sell its takeout delivery service Waimai to Alibaba-backed competitor Ele.me, according to <a href=\"https://www.wsj.com/articles/baidu-is-selling-takeout-delivery-business-to-alibaba-backed-ele-me-1503322890?mod&amp;#61;e2tw\" target=\"_blank\">The Wall Street Journal</a>.</li><li>               Sources say the deal, paid in cash and stock, will be announced this week.&nbsp;</li><li>                  Waimai has a valuation of $2.5B compared to Ele.me&rsquo;s $5.5B to $6B.    </li><li>               Waimai shareholders will get a minority stake in the combined entity created after the deal.&nbsp;</li><li>               Baidu&rsquo;s has increasingly shifted its focus towards autonomous vehicles, with its platform earning partnerships with major automakers, and in the AI space.&nbsp;</li><li>Baidu shares are&nbsp;<font color='green'>up 2.1%.</font>&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283286-baidu-sell-food-delivery-unit-competitor-discount\" target=\"_blank\">Baidu could sell food delivery unit to competitor at discount</a> (July 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3290721\" data-linked=\"WSJ: Baidu will sell takeout delivery unit this week\" data-tweet=\"$BIDU - WSJ: Baidu will sell takeout delivery unit this week https://seekingalpha.com/news/3290721-wsj-baidu-will-sell-takeout-delivery-unit-this-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3290721-wsj-baidu-will-sell-takeout-delivery-unit-this-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290719\" data-ts=\"1503331591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRKR\" target=\"_blank\">BRKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290719-bruker-debuts-new-crystallography-tools-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bruker debuts new crystallography tools; shares up 1%</a></h4><ul><li>At the 24th Congress &amp; General Assembly for the International Union of Crystallography in India, Bruker (<a href='https://seekingalpha.com/symbol/BRKR' title='Bruker Corporation'>BRKR</a> <font color='green'>+1.2%</font>) <a href=\"https://seekingalpha.com/pr/16919608-bruker-announces-novel-d8-venture-biotools-advanced-structural-biology-research-x-ray\" target=\"_blank\">unveils </a>its new D8 VENTURE BIOTOOLS for laboratory macromolecular crystallography.</li><li>The new lineup includes the ImS DIAMOND, which the company calls the world's brightest microfocus X-ray source, the latest version of the Excillum METAJET X-ray source, the PHOTON III photon-counting pixel array detector and the SCOUT automated crystal-handling system.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290719\" data-linked=\"Bruker debuts new crystallography tools; shares up 1%\" data-tweet=\"$BRKR - Bruker debuts new crystallography tools; shares up 1% https://seekingalpha.com/news/3290719-bruker-debuts-new-crystallography-tools-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3290719-bruker-debuts-new-crystallography-tools-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290717\" data-ts=\"1503331231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290717-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NC' title='NACCO Industries Inc.'>NC</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a> <font color='green'>+7%</font>.</li>     <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='red'>-9%</font>. LTEA <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290717\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NC $HLF $FCAU - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3290717-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3290717-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290702\" data-ts=\"1503329341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THC\" target=\"_blank\">THC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290702-hospital-operators-in-green-in-early-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hospital operators in the green in early trading</a></h4><ul><li>Hospital groups buck the market's selling. Tenet Healthcare (<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+17.4%</font>) is leading the charge. In a <a href=\"https://www.sec.gov/Archives/edgar/data/70318/000165495417007779/camberthc201713g.htm\" target=\"_blank\">13G filed today</a>, institutional investor Camber Capital Management LLC disclosed a 5.7% stake.</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='green'>+8.8%</font>)(<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a> <font color='green'>+1.1%</font>)(<a href='https://seekingalpha.com/symbol/LPNT' title='LifePoint Health, Inc.'>LPNT</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='green'>+1.2%</font>)(<a href='https://seekingalpha.com/symbol/SEM' title='Select Medical Holdings Corporation'>SEM</a> <font color='green'>+0.6%</font>)(<a href='https://seekingalpha.com/symbol/UHS' title='Universal Health Services Inc.'>UHS</a> <font color='green'>+0.6%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3290702\" data-linked=\"Hospital operators in the green in early trading\" data-tweet=\"$THC $THC $CYH - Hospital operators in the green in early trading https://seekingalpha.com/news/3290702-hospital-operators-in-green-in-early-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3290702-hospital-operators-in-green-in-early-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290700\" data-ts=\"1503328684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUS\" target=\"_blank\">NUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290700-herbalife-rally-stokes-mlm-compatriots-nu-skin-and-usana\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herbalife rally stokes MLM compatriots Nu Skin and USANA</a></h4><ul><li>Multilevel marketers Nu Skin Enterprises (<a href='https://seekingalpha.com/symbol/NUS' title='Nu Skin Enterprises Inc.'>NUS</a> <font color='green'>+2.8%</font>) and USANA Health Sciences (<a href='https://seekingalpha.com/symbol/USNA' title='USANA Health Sciences Inc.'>USNA</a> <font color='green'>+2.1%</font>) are both up in early trading as the buying ripples out from Herbalife (<a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a> <font color='green'>+11.5%</font>) which announced go-private discussions with investor Carl Icahn.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290625-herbalife-launches-offer-buy-600m-common-stock-sellers-receive-cvr-go-private-deal-shares-8\" target=\"_blank\">Herbalife launches offer to buy $600M of common stock, sellers to receive CVR for go-private deal; shares up 8% premarket</a> (Aug. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3290700\" data-linked=\"Herbalife rally stokes MLM compatriots Nu Skin and USANA\" data-tweet=\"$NUS $NUS $USNA - Herbalife rally stokes MLM compatriots Nu Skin and USANA https://seekingalpha.com/news/3290700-herbalife-rally-stokes-mlm-compatriots-nu-skin-and-usana?source=tweet\" data-url=\"https://seekingalpha.com/news/3290700-herbalife-rally-stokes-mlm-compatriots-nu-skin-and-usana\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290698\" data-ts=\"1503328553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DGLY\" target=\"_blank\">DGLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290698-digital-ally-prices-3m-offering-shares-down-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Ally prices $3M offering; shares down 12%</a></h4><ul><li>        Digital Ally (NASDAQ:<a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a>) announces the pricing of a $3M equity offering of common stock and warrants with institutional investors.</li><li>               The agreement includes an aggregate of 1M shares of common stock at $3 per share.&nbsp;</li><li>               Digital Ally will use the proceeds to retire $1M of Secured Convertible Debentures, the entire $700K principal of subordinated notes, and the remainder for general corporate purposes.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16919934-digital-ally-prices-3_0-million-registered-equity-offering\" target=\"_blank\">Press release</a>&nbsp;</li><li>Digital Ally shares are&nbsp;<font color='red'>down 12.2%</font>. &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3290698\" data-linked=\"Digital Ally prices $3M offering; shares down 12%\" data-tweet=\"$DGLY - Digital Ally prices $3M offering; shares down 12% https://seekingalpha.com/news/3290698-digital-ally-prices-3m-offering-shares-down-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3290698-digital-ally-prices-3m-offering-shares-down-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290697\" data-ts=\"1503328111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSBR\" target=\"_blank\">CSBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290697-champions-oncology-teams-up-astrazeneca-to-develop-xenograft-models-for-oncology-r-and-d\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Champions Oncology teams up with AstraZeneca to develop xenograft models for oncology R&amp;D; shares ahead 8%</a></h4><ul><li>Thinly traded nano cap Champions Oncology (<a href='https://seekingalpha.com/symbol/CSBR' title='Champions Oncology, Inc.'>CSBR</a> <font color='green'>+7.6%</font>) is up on more than 4x normal volume, albeit on turnover of only 65K shares, in response to its&nbsp;<a href=\"https://seekingalpha.com/pr/16919755-champions-oncology-announces-strategic-collaboration-astrazeneca-develop-unique-cohorts\" target=\"_blank\">strategic collaboration</a> with AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='red'>-0.6%</font>) to develop unique cohorts of patient-derived xenograft &#40;PDX&#41; models that AZN will use in its oncology R&amp;D programs in breast and lung cancer. Champions will add them to its TumorGraft bank for translational oncology research for academic and industry customers.</li><li>The new cohorts will expand Champions' lineup of estrogen receptor-positive metastatic breast cancer and epidermal growth factor receptor-mutant non-small cell lung cancer PDX models. Both will focus on the metastatic, previously treated setting.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290697\" data-linked=\"Champions Oncology teams up with AstraZeneca to develop xenograft models for oncology R&amp;D; shares ahead 8%\" data-tweet=\"$CSBR $CSBR $AZN - Champions Oncology teams up with AstraZeneca to develop xenograft models for oncology R&amp;D; shares ahead 8% https://seekingalpha.com/news/3290697-champions-oncology-teams-up-astrazeneca-to-develop-xenograft-models-for-oncology-r-and-d?source=tweet\" data-url=\"https://seekingalpha.com/news/3290697-champions-oncology-teams-up-astrazeneca-to-develop-xenograft-models-for-oncology-r-and-d\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290667\" data-ts=\"1503327679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290667-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/PAVM' title='PAVmed Inc.'>PAVM</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> CRME <font color='red'>-39%</font>. <a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CATS' title='Catasys Inc.'>CATS</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290667\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$THC $CHRS $NTLA - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3290667-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3290667-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290687\" data-ts=\"1503326943\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290687-trovagenes-pcmminus-075-demonstrates-synergy-hdac-inhibitor-in-nhl-cell-lines-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene&#39;s PCM-075 demonstrates synergy with HDAC inhibitor in NHL cell lines; shares ahead 3%</a></h4><ul><li>Nano cap Trovagene (<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a> <font color='green'>+3.1%</font>) perks up on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16919663-trovagenes-plk1-inhibitor-pcmminus-075-demonstrates-synergy-hdac-inhibitor-non-hodgkin\" target=\"_blank\">announcement </a>of encouraging preclinical data on PLK1 inhibitor PCM-075.</li><li>The company says PCM-075, in combination with an HDAC inhibitor, showed \"significant synergy of up to 80%\" in aggressive double-hit B-cell lymphoma and mantle-cell lymphoma cell lines.</li><li>CEO Bill Welch says, \"We are excited to see the synergistic benefits with PCM-075 in combination with a HDAC inhibitor in the most difficult cell lines in NHL. This data complements our recent announcement of an in-vivo study demonstrating synergy of PCM-075 with a leading investigational FLT3 inhibitor, as well as PCM-075 synergy with many chemotherapeutics. We have an active Investigational New Drug &#40;IND&#41; in place with the FDA for each of solid tumors and hematologic malignancies, which could facilitate the development of PCM-075 across a number of cancer types.\"</li><li>Trovagene plans to initiate clinical trials assessing PCM-075 in AML. It says PCM-075's value proposition compared to other PLK1 inhibitors is higher selectivity, greater potency, oral bioavailability and shorter half-life.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290687\" data-linked=\"Trovagene&#39;s PCM-075 demonstrates synergy with HDAC inhibitor in NHL cell lines; shares ahead 3%\" data-tweet=\"$TROV - Trovagene&#39;s PCM-075 demonstrates synergy with HDAC inhibitor in NHL cell lines; shares ahead 3% https://seekingalpha.com/news/3290687-trovagenes-pcmminus-075-demonstrates-synergy-hdac-inhibitor-in-nhl-cell-lines-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3290687-trovagenes-pcmminus-075-demonstrates-synergy-hdac-inhibitor-in-nhl-cell-lines-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290683\" data-ts=\"1503325702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHRS\" target=\"_blank\">CHRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290683-coherus-bio-nabs-150m-private-equity-placement-first-half-to-be-issued-month-end-11_44-per\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coherus Bio nabs $150M private equity placement, first half to be issued at month-end at $11.44 per share; shares ahead 17%</a></h4><ul><li>Coherus BioSciences (<a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='green'>+16.7%</font>) <a href=\"https://seekingalpha.com/pr/16919788-coherus-secures-private-placement-temasek\" target=\"_blank\">inks a deal</a> with Singapore-based Temasek for the private placement of $150M in common stock in two tranches. The first tranche of $75M, consisting of 6,556,116 common shares at $11.44 per share, will be funded by August 31. The second tranche will be funded following the projected FDA approval of CHS-1701, a biosimilar of Amgen's Neulasta (pegfilgrastim).</li><li>The new capital will fund the completion of development, registration and commercial launch of CHS-1701, the development and registration of CHS-1420, a biosimilar of AbbVie's Humira (adalimumab), the development of CHS-3351, a biosimilar of Roche's Lucentis (ranibizumab), and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290683\" data-linked=\"Coherus Bio nabs $150M private equity placement, first half to be issued at month-end at $11.44 per share; shares ahead 17%\" data-tweet=\"$CHRS - Coherus Bio nabs $150M private equity placement, first half to be issued at month-end at $11.44 per share; shares ahead 17% https://seekingalpha.com/news/3290683-coherus-bio-nabs-150m-private-equity-placement-first-half-to-be-issued-month-end-11_44-per?source=tweet\" data-url=\"https://seekingalpha.com/news/3290683-coherus-bio-nabs-150m-private-equity-placement-first-half-to-be-issued-month-end-11_44-per\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290682\" data-ts=\"1503325542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEO\" target=\"_blank\">AEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290682-investors-back-away-from-apparel-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors back away from apparel stocks</a></h4><ul> <li>The sell-off in sports retail is broadening out to include other apparal stocks. Several sell-side analysts have dropped profit estimates on retailers as the reset kickstarted last week by Foot Locker's guidance cut extends.</li> <li>A partial list of decliners includes American Eagle Oufitters (NYSE:<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a>)&nbsp;<font color='red'>-6.52%</font>, Gap (NYSE:<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a>)&nbsp;<font color='red'>-2.21%</font>, Abercrombie &amp; Fitch (NYSE:<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a>)&nbsp;<font color='red'>-5.28%</font>, Express (NYSE:<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a>)&nbsp;<font color='red'>-5.53%</font>, Guess (NYSE:<a href='https://seekingalpha.com/symbol/GES' title='Guess? Inc.'>GES</a>) -3.98%, Urban Outfitters (NASDAQ:<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a>)&nbsp;<font color='red'>-1.96%</font>, Tailored Brands (NYSE:<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a>)&nbsp;<font color='red'>-4.38%</font>, Boot Barn (NASDAQ:<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a>)&nbsp;<font color='red'>-3.47%</font>, J. Jill (NYSE:<a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>)&nbsp;<font color='red'>-2.86%</font>, New York &amp; Company (NWY)&nbsp;<font color='red'>-2.74%</font>, Tilly's (NYSE:<a href='https://seekingalpha.com/symbol/TLYS' title='Tilly&#39;s, Inc.'>TLYS</a>)&nbsp;<font color='red'>-2.34%</font>, Genesco (NYSE:<a href='https://seekingalpha.com/symbol/GCO' title='Genesco Inc.'>GCO</a>)<font color='red'> -7.22%</font>, Under Armour (NYSE:<a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a>)&nbsp;<font color='red'>-3.21%</font>, Canada Goose (NYSE:<a href='https://seekingalpha.com/symbol/GOOS' title='Canada Goose Holdings'>GOOS</a>)&nbsp;<font color='red'>-2.29%</font>, Perry Ellis International (NASDAQ:<a href='https://seekingalpha.com/symbol/PERY' title='Perry Ellis International Inc.'>PERY</a>)&nbsp;<font color='red'>-2.14%</font>, Crocs (NASDAQ:<a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a>)&nbsp;<font color='red'>-2.48%</font>, Fossil (NASDAQ:<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a>)&nbsp;<font color='red'>-2.40%</font>, Caleres (NYSE:<a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a>)&nbsp;<font color='red'>-2.30%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3290682\" data-linked=\"Investors back away from apparel stocks\" data-tweet=\"$AEO $AEO $GPS - Investors back away from apparel stocks https://seekingalpha.com/news/3290682-investors-back-away-from-apparel-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3290682-investors-back-away-from-apparel-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290679\" data-ts=\"1503324650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATLT\" target=\"_blank\">ATLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290679-atlas-technology-lower-15-on-4q17-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atlas Technology lower 15% on 4Q17 guidance</a></h4><ul>     <li>Atlas Technology (<a href='https://seekingalpha.com/symbol/ATLT' title='Atlas Technology International Inc.'>OTC:ATLT</a>) <font color='red'>-15.1%</font> expects 4Q17 revenues in the range of $1.6M - $1.8M (+32% Q/Q).</li><li>4Q17 net income is expected to be in the range of between $180k to 220k.</li><li><a href=\"https://seekingalpha.com/pr/16919911-atlas-technology-international-sees-record-fourth-fiscal-quarter\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3290679\" data-linked=\"Atlas Technology lower 15% on 4Q17 guidance\" data-tweet=\"$ATLT - Atlas Technology lower 15% on 4Q17 guidance https://seekingalpha.com/news/3290679-atlas-technology-lower-15-on-4q17-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3290679-atlas-technology-lower-15-on-4q17-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290678\" data-ts=\"1503324493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GHL\" target=\"_blank\">GHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290678-greenhill-down-another-3-ubs-cuts-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Greenhill down another 3% as UBS cuts price target</a></h4><ul><li>Despite a&nbsp;<font color='red'>45% year-to-date decline</font>, the Greenhill (NYSE:<a href='https://seekingalpha.com/symbol/GHL' title='Greenhill & Co., Inc.'>GHL</a>) continues to trade at a premium to peers, says UBS's Breenan Hawken, cutting his price target to a Street-low $9 from $17.</li><li>He takes note of continued growth difficulties, \"very weak\" pipeline, and a highly levered balance sheet which could put the dividend at risk.</li><li>Shares are&nbsp;<font color='red'>down 2.85%&nbsp;</font>to $15.35.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290678\" data-linked=\"Greenhill down another 3% as UBS cuts price target\" data-tweet=\"$GHL - Greenhill down another 3% as UBS cuts price target https://seekingalpha.com/news/3290678-greenhill-down-another-3-ubs-cuts-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3290678-greenhill-down-another-3-ubs-cuts-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290674\" data-ts=\"1503323902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290674-nike-slumps-after-jefferies-warns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike slumps after Jefferies warns</a></h4><ul> <li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) <font color='red'>drops another 2.95%</font> after Jefferies <a href=\"http://www.marketwatch.com/story/nike-downgraded-on-increased-competition-and-growth-risk-2017-08-21\" target=\"_blank\">lowers</a> the stock to a Hold rating from Buy on concerns about competition from Adidas.</li> <li>Analyst Randal Konik relies on several data sources showing strength for the Adidas brand in raising caution on Nike.</li> <li>\"Secular industry tailwinds still exist, but Adidas brand heat dilutes them, and Nike innovation is strong, but there's less buzz around its near-term pipeline,\" writes Konik.</li> <li>The price target on Nike is slashed to $60 from $75.</li><li>Shares of Nike are down almost 10% over the last week.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290674\" data-linked=\"Nike slumps after Jefferies warns\" data-tweet=\"$NKE - Nike slumps after Jefferies warns https://seekingalpha.com/news/3290674-nike-slumps-after-jefferies-warns?source=tweet\" data-url=\"https://seekingalpha.com/news/3290674-nike-slumps-after-jefferies-warns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290673\" data-ts=\"1503323854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTR\" target=\"_blank\">CYTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290673-cytrx-plans-to-reverse-split-stock-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytRx plans to reverse split stock; shares down 7%</a></h4><ul><li>CytRx (<a href='https://seekingalpha.com/symbol/CYTR' title='CytRx Corporation'>CYTR</a> <font color='red'>-7.1%</font>) <a href=\"https://seekingalpha.com/pr/16919867-cytrx-corporation-files-preliminary-proxy-statement-upcoming-special-meeting\" target=\"_blank\">files </a>a preliminary proxy statement with the SEC for a planned special meeting of shareholders to authorize a reverse split of its common shares in order to regain compliance with the Nasdaq listing requirement of a $1 minimum bid price. Definitive proxy materials should be mailed during the week of September 5.</li><li><strong>Update</strong>: On August 30, the company <a href=\"https://seekingalpha.com/pr/16927291-cytrx-corporation-files-definitive-proxy-statement-upcoming-special-meeting\" target=\"_blank\">announced </a>that it will seek shareholder approval for a 1:6 reverse split of its common shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290673\" data-linked=\"CytRx plans to reverse split stock; shares down 7%\" data-tweet=\"$CYTR - CytRx plans to reverse split stock; shares down 7% https://seekingalpha.com/news/3290673-cytrx-plans-to-reverse-split-stock-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3290673-cytrx-plans-to-reverse-split-stock-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290672\" data-ts=\"1503323617\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHU\" target=\"_blank\">CHU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290672-china-unicomplus-3_3-11_7b-reform-plan-gets-regulatory-ok\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Unicom +3.3% as $11.7B reform plan gets regulatory OK</a></h4><ul>   <li>China Unicom (NYSE:<a href='https://seekingalpha.com/symbol/CHU' title='China Unicom &#40;Hong Kong&#41; Limited'>CHU</a>) is <font color='green'>up 3.3%</font> out of the open in NYSE trading, following similar moves up in Asia today after a somewhat chaotic ownership reform plan got a <a href=\"https://www.reuters.com/article/us-china-unicom-sale-idUSKCN1B101N?feedType=nl&amp;feedName=innovationNews&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=US%20Deals%20Today%202017-08-21&amp;utm_term=US%20Deals%20Today\" target=\"_blank\">sign-off from regulators</a>.</li>    <li>The stock resumed trading in Hong Kong after a <a href=\"https://seekingalpha.com/news/3290194-china-unicom-pulls-11_7b-mixed-ownership-plan-amid-confusion\" target=\"_blank\">Wednesday suspension</a>. Some confusion reigned over whether all arrangements had been made for a compliant placement.</li>    <li>But China's securities regulator says the $11.7B mixed-ownership plan doesn't violate the rules.</li>    <li>\"After going through the relevant legal procedures with the National Development and Reform Commission &#40;NDRC&#41; and other departments, the China Securities and Reform Commission &#40;CSRC&#41; will treat the private placement in China Unicom's ownership reform as an exceptional case,\" the CSRC said.</li>    <li>More than a dozen major investors are taking part in the sizable placement, including Alibaba, Tencent and Baidu.</li>    <li>Also up are China's other state-owned telecoms: China Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CHL' title='China Mobile Limited'>CHL</a>) <font color='green'>up 1.1%</font>; China Telecom (NYSE:<a href='https://seekingalpha.com/symbol/CHA' title='China Telecom Corporation Limited'>CHA</a>) <font color='green'>+1.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290672\" data-linked=\"China Unicom +3.3% as $11.7B reform plan gets regulatory OK\" data-tweet=\"$CHU $CHU $CHL - China Unicom +3.3% as $11.7B reform plan gets regulatory OK https://seekingalpha.com/news/3290672-china-unicomplus-3_3-11_7b-reform-plan-gets-regulatory-ok?source=tweet\" data-url=\"https://seekingalpha.com/news/3290672-china-unicomplus-3_3-11_7b-reform-plan-gets-regulatory-ok\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290669\" data-ts=\"1503323376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290669-shire-finance-chief-to-leave-year-end-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire finance chief to leave at year-end; shares down 3%</a></h4><ul><li>Shire plc (<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a> <font color='red'>-3.3%</font>) Chief Financial Officer Jeff Poulton will <a href=\"https://seekingalpha.com/pr/16919896-shire-plc-director-senior-management-changes\" target=\"_blank\">leave the company</a> at year-end to take the CFO job at a Boston-based startup called Indigo Ag. A search for a successor is underway.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290669\" data-linked=\"Shire finance chief to leave at year-end; shares down 3%\" data-tweet=\"$SHPG - Shire finance chief to leave at year-end; shares down 3% https://seekingalpha.com/news/3290669-shire-finance-chief-to-leave-year-end-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3290669-shire-finance-chief-to-leave-year-end-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290665\" data-ts=\"1503322973\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALXN\" target=\"_blank\">ALXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290665-alexions-soliris-okd-in-europe-for-certain-patients-myasthenia-gravis-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexion&#39;s Soliris OK&#39;d in Europe for certain patients with myasthenia gravis; shares up 2%</a></h4><ul><li>The European Commission <a href=\"https://seekingalpha.com/pr/16919930-european-commission-grants-new-indication-soliris-eculizumab-treatment-patients-refractory\" target=\"_blank\">approves </a>the use of Alexion Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='green'>+1.5%</font>) Soliris (eculizumab) for treatment of adults with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive, an ultra-rare subset of gMG patients.</li><li>Its marketing applications are under review in the U.S. and Japan.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290665\" data-linked=\"Alexion&#39;s Soliris OK&#39;d in Europe for certain patients with myasthenia gravis; shares up 2%\" data-tweet=\"$ALXN - Alexion&#39;s Soliris OK&#39;d in Europe for certain patients with myasthenia gravis; shares up 2% https://seekingalpha.com/news/3290665-alexions-soliris-okd-in-europe-for-certain-patients-myasthenia-gravis-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3290665-alexions-soliris-okd-in-europe-for-certain-patients-myasthenia-gravis-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290659\" data-ts=\"1503322445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMU\" target=\"_blank\">IMMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290659-immunomedics-immuminus-130-extends-survival-in-mid-stage-crc-study-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immunomedics&#39; IMMU-130 extends survival in mid-stage CRC study; shares up 1%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16919714-immunomedics-announces-publication-phase-2-results-labetuzumab-govitecan-immuminus-130\" target=\"_blank\">Preliminary data</a> from a Phase 2 clinical trial assessing Immunomedics' (<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='green'>+1.2%</font>) IMMU-130 ( labetuzumab govitecan) in heavily pretreated patients with metastatic colorectal cancer &#40;CRC&#41; showed a positive treatment effect.</li><li>Patients receiving once-weekly doses of 8 mg/kg (n=21) or 10 mg/kg (n=22) of labetuzumab govitecan experienced median progression-free survival &#40;PFS&#41;&nbsp;of 4.6 months and 3.6 months, respectively. Median overall survival &#40;OS&#41; was 7.5 months and 6.4 months, respectively. All received previous irinotecan therapy.</li><li>In a subset (n=23) of patients previously treated with Bayer's Stivarga (regorafenib), median PFS and OS were 4.0 months and 6.7 months, respectively, which was better than 2.0 months and 6.4 months, respectively, in Stivarga's dataset supporting its U.S. approval.</li><li>The development of IMMU-130 is ongoing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290659\" data-linked=\"Immunomedics&#39; IMMU-130 extends survival in mid-stage CRC study; shares up 1%\" data-tweet=\"$IMMU - Immunomedics&#39; IMMU-130 extends survival in mid-stage CRC study; shares up 1% https://seekingalpha.com/news/3290659-immunomedics-immuminus-130-extends-survival-in-mid-stage-crc-study-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3290659-immunomedics-immuminus-130-extends-survival-in-mid-stage-crc-study-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290654\" data-ts=\"1503322076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290654-freeport-mcmoran-keeps-climbing-investors-pile-industrial-metals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Freeport McMoRan keeps climbing as investors pile into industrial metals</a></h4><ul>     <li>Freeport McMoRan (NYSE:<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a>) <font color='green'>+2.8%</font> premarket on <a href=\"https://asia.nikkei.com/Markets/Commodities/Copper-zinc-prices-rising-as-supply-tightens-demand-grows\" target=\"_blank\">continued optimism</a> over strength in prices of copper, zinc and other industrial metals, as supply is constrained while demand remains strong.</li>     <li>Market dynamics have led the metals' prices, which were on a downtrend until rebounding in early June, and speculators also have entered the picture; FCX has climbed more than 20% since mid-June.</li>     <li>The recovery in copper and some other base metals &ldquo;has really only just begun. <a href=\"https://www.wsj.com/articles/booming-metals-rally-signals-optimism-on-global-growth-1503307804\" target=\"_blank\">There's much more to go</a>,&rdquo; says Jefferies analyst Christopher LaFemina.</li>     <li>Separately, FCX expects to <a href=\"https://www.reuters.com/article/us-indonesia-freeport-idUSKCN1B00LS\" target=\"_blank\">regain limited access</a> to the Grasberg copper mine in Indonesia today after hundreds of former workers blockaded the site and clashed with police over the weekend; trouble began Saturday afternoon during a demonstration over employment terms.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290654\" data-linked=\"Freeport McMoRan keeps climbing as investors pile into industrial metals\" data-tweet=\"$FCX - Freeport McMoRan keeps climbing as investors pile into industrial metals https://seekingalpha.com/news/3290654-freeport-mcmoran-keeps-climbing-investors-pile-industrial-metals?source=tweet\" data-url=\"https://seekingalpha.com/news/3290654-freeport-mcmoran-keeps-climbing-investors-pile-industrial-metals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290651\" data-ts=\"1503321390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290651-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/JMEI' title='Jumei International Holding Limited'>JMEI</a> <font color='green'>+9%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/WUBA' title='58.com Inc.'>WUBA</a> <font color='green'>+9%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3290558\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/TSEM' title='Tower Semiconductor Ltd.'>TSEM</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3290645-towerjazz-announces-milestone-payment-chinese-fab-shares-8-percent\" target=\"_blank\">payment</a> from Chinese fab.</li>     <li><a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a> <font color='green'>+7%&nbsp;</font>on launching offer to buy $600M of common stock.</li>     <li><a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3290639-tonix-pharma-set-present-data-ptsd-candidate-tnxminus-102-sl-military-health-meeting-shares\" target=\"_blank\">presenting</a> data on PTSD candidate TNX-102 SL.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290651\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$JMEI $WUBA $TSEM - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3290651-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3290651-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290648\" data-ts=\"1503321175\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORV\" target=\"_blank\">CORV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290648-cardiome-not-quite-on-resubmission-of-brinavess-nda-shares-down-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardiome not quite there on resubmission of Brinavess NDA; shares down 5% premarket</a></h4><ul><li>Thinly traded micro cap Cardiome (CRME) is down&nbsp;<font color='red'>5%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16919662-cardiome-provides-u-s-regulatory-update-brinavess\" target=\"_blank\">announcement </a>that the FDA has informed it that its proposed data package is not sufficient to support a resubmission of the BRINAVESS (vernakalant hydrochloride IV) New Drug Application &#40;NDA&#41; for the treatment of atrial fibrillation.</li><li>The company wanted to refile the NDA using the original dataset, six years of real-world safety data based on sales of BRINAVESS in 33 countries, interim data from the SPECTRUM study and preclinical data from studies performed at the agency's request.</li><li>It says it will continue working with the FDA as it considers its regulatory options.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3251056-cardiome-cleared-commercialize-brinavess-canada-shares-ahead-2-percent\" target=\"_blank\">Cardiome cleared to commercialize Brinavess in Canada; shares ahead 2%</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3290648\" data-linked=\"Cardiome not quite there on resubmission of Brinavess NDA; shares down 5% premarket\" data-tweet=\"$CORV - Cardiome not quite there on resubmission of Brinavess NDA; shares down 5% premarket https://seekingalpha.com/news/3290648-cardiome-not-quite-on-resubmission-of-brinavess-nda-shares-down-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3290648-cardiome-not-quite-on-resubmission-of-brinavess-nda-shares-down-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290647\" data-ts=\"1503320990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290647-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-12%</font>.</li><li><a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a>&nbsp;<font color='red'>-12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3290601-francescas-updates-guidance-announces-cmo-resignation\" target=\"_blank\">updating</a> guidance announcing CMO resignation.</li><li><a href='https://seekingalpha.com/symbol/INFY' title='Infosys Limited, Inc.'>INFY</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3290559-infosys-offers-buyback-ceo-quits\" target=\"_blank\">offering</a> buyback after CEO's resignation.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3290647\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$RTNB $FRAN $INFY - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3290647-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3290647-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290645\" data-ts=\"1503320952\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSEM\" target=\"_blank\">TSEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290645-towerjazz-announces-milestone-payment-for-chinese-fab-shares-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TowerJazz announces milestone payment for Chinese fab; shares up 8%</a></h4><ul><li>        TowerJazz (NASDAQ:<a href='https://seekingalpha.com/symbol/TSEM' title='Tower Semiconductor Ltd.'>TSEM</a>) and Tacoma Technology announce that Tower has received an initial $18M payment related to the establishment of an 8-inch semiconductor fabrication facility in China.</li><li>               The payment renders the phase one agreement binding.&nbsp;</li><li>               TowerJazz will provide the tech with operational and integration consultation for the facility and will receive additional milestone payments over the coming years.&nbsp;</li><li>               <a href=\"http://ir.towerjazz.com/phoenix.zhtml?c=79678&amp;p=RssLanding&amp;cat=news&amp;id=2294764\" target=\"_blank\">Press release</a>&nbsp;</li><li>                  TowerJazz shares are&nbsp;<font color='green'>up 8.07%</font>&nbsp;premarket.    &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3290645\" data-linked=\"TowerJazz announces milestone payment for Chinese fab; shares up 8%\" data-tweet=\"$TSEM - TowerJazz announces milestone payment for Chinese fab; shares up 8% https://seekingalpha.com/news/3290645-towerjazz-announces-milestone-payment-for-chinese-fab-shares-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3290645-towerjazz-announces-milestone-payment-for-chinese-fab-shares-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290644\" data-ts=\"1503320748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290644-finish-line-slides-again-after-ubs-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finish Line slides again after UBS downgrades</a></h4><ul> <li>Shares of Finish Line (NASDAQ:<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a>) are crumbling again after UBS <a href=\"http://www.barrons.com/articles/stocks-to-watch-nike-drops-on-downgrade-sempra-gains-after-beating-buffett-1503317891\" target=\"_blank\">lowers</a> the retailer to a Sell rating.</li> <li>The firm drops its estimates for Finish Line's margins in reaction to last week's Foot Locker guidance cut. The price target is slashed to $37 from $70.</li> <li>FINL&nbsp;<font color='red'>-3.72%</font> premarket to $10.60 vs. a 52-week trading range of $10.49 to $24.52. Finish Line fell 18% last week.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290419-sports-retail-tailspin-foot-locker-earnings-dud\" target=\"_blank\">Sports retail in a tailspin after Foot Locker earnings dud</a> (Aug. 18)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290644\" data-linked=\"Finish Line slides again after UBS downgrades\" data-tweet=\"$FINL - Finish Line slides again after UBS downgrades https://seekingalpha.com/news/3290644-finish-line-slides-again-after-ubs-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3290644-finish-line-slides-again-after-ubs-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290639\" data-ts=\"1503320148\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290639-tonix-pharma-set-to-present-data-on-ptsd-candidate-tnxminus-102-sl-military-health-meeting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharma set to present data on PTSD candidate TNX-102 SL at military health meeting; shares ahead 7% premarket</a></h4><ul><li>Thinly traded nano cap Tonix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16919621-tonix-pharmaceuticals-present-additional-phase-2-clinical-results-design-ongoing-phase-3\" target=\"_blank\">announcement</a> that it will be presenting data on PTSD candidate TNX-102 SL, branded as Tonmya, at the Military Health Systems Research Symposium, August 27-30, in Kissimmee, FL.</li><li>A Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03062540\" target=\"_blank\">HONOR</a>, is ongoing.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3254129-tonix-big-start-late-stage-study-tnxminus-102-sl-shares-ahead-66-percent-premarket\" target=\"_blank\">Tonix up big on start of late-stage study of TNX-102 SL; shares ahead 66% premarket</a> (March 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3290639\" data-linked=\"Tonix Pharma set to present data on PTSD candidate TNX-102 SL at military health meeting; shares ahead 7% premarket\" data-tweet=\"$TNXP - Tonix Pharma set to present data on PTSD candidate TNX-102 SL at military health meeting; shares ahead 7% premarket https://seekingalpha.com/news/3290639-tonix-pharma-set-to-present-data-on-ptsd-candidate-tnxminus-102-sl-military-health-meeting?source=tweet\" data-url=\"https://seekingalpha.com/news/3290639-tonix-pharma-set-to-present-data-on-ptsd-candidate-tnxminus-102-sl-military-health-meeting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290631\" data-ts=\"1503319323\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRWD\" target=\"_blank\">IRWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290631-fda-oks-ironwoods-duzallo-for-gout-related-hyperuricemia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Ironwood&#39;s Duzallo for gout-related hyperuricemia</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16919681-ironwood-pharmaceuticals-announces-fda-approval-duzallo-lesinurad-allopurinol-treatment\" target=\"_blank\">approves </a>Ironwood Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/IRWD' title='Ironwood Pharmaceuticals, Inc.'>IRWD</a>) DUZALLO (lesinurad and allopurinol) for the treatment of hyperuricemia (excess uric acid in the blood) in gout patients who have not achieved target serum uric acid levels with allopurinol alone.</li><li>Commercial launch will commence in Q4.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3233409-fda-review-ironwoods-marketing-application-gout-drug-duzallo-action-date-h2\" target=\"_blank\">FDA to review Ironwood's marketing application for gout drug Duzallo, action date in H2</a> (Jan. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3290631\" data-linked=\"FDA OKs Ironwood&#39;s Duzallo for gout-related hyperuricemia\" data-tweet=\"$IRWD - FDA OKs Ironwood&#39;s Duzallo for gout-related hyperuricemia https://seekingalpha.com/news/3290631-fda-oks-ironwoods-duzallo-for-gout-related-hyperuricemia?source=tweet\" data-url=\"https://seekingalpha.com/news/3290631-fda-oks-ironwoods-duzallo-for-gout-related-hyperuricemia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290625\" data-ts=\"1503318504\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLF\" target=\"_blank\">HLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290625-herbalife-launches-offer-to-buy-600m-of-common-stock-sellers-to-receive-cvr-for-go-private\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herbalife launches offer to buy $600M of common stock, sellers to receive CVR for go-private deal; shares up 8% premarket</a></h4><ul><li>Herbalife (NYSE:<a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a>) <a href=\"https://seekingalpha.com/pr/16919669-herbalife-announces-self-tender-offer-seeking-purchase-600-million-outstanding-common-shares\" target=\"_blank\">commences </a>a self-tender offer to buy up to $600M of its common stock at $60 - 68 per share. For each share tendered, investors will receive a non-transferable contractual contingent value right &#40;CVR&#41; that will pay out if the company is acquired in a go-private transaction within two years. The tender offer will expire on September 19 at 5:00 pm ET.</li><li>The company says it was recently in discussions with an investor (appears to be Carl Icahn) regarding a deal that could have led to the company going private. The talks ended on August 16.</li><li>CFO John DeSimone says, &ldquo;Our Board and management team are committed to enhancing shareholder value and we believe today&rsquo;s action is just one more step in meeting this goal. We have already acquired during 2017 approximately $299 million of our shares on the open market under our current $1.5 billion share repurchase plan, and we believe this tender offer provides us an efficient way to buy back additional shares at an attractive price.&rdquo;</li><li>In connection with the tender offer, the company inked an agreement with Mr. Icahn under which he (and his affiliates) agreed not to increase his ownership above 50% unless he goes all in and acquires 100%.</li><li>Shares are up&nbsp;<font color='green'>8%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290625\" data-linked=\"Herbalife launches offer to buy $600M of common stock, sellers to receive CVR for go-private deal; shares up 8% premarket\" data-tweet=\"$HLF - Herbalife launches offer to buy $600M of common stock, sellers to receive CVR for go-private deal; shares up 8% premarket https://seekingalpha.com/news/3290625-herbalife-launches-offer-to-buy-600m-of-common-stock-sellers-to-receive-cvr-for-go-private?source=tweet\" data-url=\"https://seekingalpha.com/news/3290625-herbalife-launches-offer-to-buy-600m-of-common-stock-sellers-to-receive-cvr-for-go-private\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>132&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290619\" data-ts=\"1503317451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMKAF\" target=\"_blank\">AMKAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290619-total-deal-for-maersk-oil-catapults-uppermost-tier-of-world-producers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Total deal for Maersk Oil catapults it into uppermost tier of world producers</a></h4><ul>     <li>Maersk (<a href='https://seekingalpha.com/symbol/AMKAF' title='A.P. Moeller-Maersk A/SA'>OTCPK:AMKAF</a>, <a href='https://seekingalpha.com/symbol/AMKBF' title='A.P. Moeller-Maersk A/SB'>OTCPK:AMKBF</a>) is more than 3% higher in Copenhagen after <a href=\"https://seekingalpha.com/news/3290564-total-scoops-maersk-oil-unit-7_5b\" target=\"_blank\">agreeing to sell</a> its oil and gas unit to France's Total (NYSE:<a href='https://seekingalpha.com/symbol/TOT' title='TOTAL S.A.'>TOT</a>) for $4.95B plus $2.5B in debt; TOT <font color='red'>-0.4%</font> U.S. premarket.</li>     <li>The deal raises TOT's position among the world's largest oil companies; by 2019, TOT sees its production reaching 3M bbl/day of oil and gas, a level achieved by only a handful of private companies: Exxon (NYSE:<a href='https://seekingalpha.com/symbol/XOM' title='Exxon Mobil Corporation'>XOM</a>), Shell (<a href='https://seekingalpha.com/symbol/RDS.A' title='Royal Dutch Shell plc'>RDS.A</a>, <a href='https://seekingalpha.com/symbol/RDS.B' title='Royal Dutch Shell plc'>RDS.B</a>), Chevron (NYSE:<a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a>) and <a href='https://seekingalpha.com/symbol/BP' title='BP p.l.c.'>BP</a>.</li>     <li>The acquisition gives TOT ~1B boe of proven and probable reserves, ~80% in the North Sea, and will add 160K boe/day to production next year, rising to 200K/day by 2020.</li>     <li>TOT expects the deal to generate operational, commercial and financial synergies of more than $400M/year, particularly by combining assets in the North Sea, and is set to <a href=\"http://www.reuters.com/article/us-maersk-oil-m-a-total-costs-idUSKCN1B114A?il=0\" target=\"_blank\">increase its target for $4B of cost savings</a> by 2018, CEO Patrick Pouyanne says; 2018 capex will remain at $15B-$17B.</li>     <li>TOT will issue to Maersk 97.5M shares, or ~3.75% of its enlarged share capital, making the Danish company TOT's second largest shareholder.</li></ul><div class=\"tiny-share-widget\" data-id=\"3290619\" data-linked=\"Total deal for Maersk Oil catapults it into uppermost tier of world producers\" data-tweet=\"$AMKAF $AMKAF $AMKBF - Total deal for Maersk Oil catapults it into uppermost tier of world producers https://seekingalpha.com/news/3290619-total-deal-for-maersk-oil-catapults-uppermost-tier-of-world-producers?source=tweet\" data-url=\"https://seekingalpha.com/news/3290619-total-deal-for-maersk-oil-catapults-uppermost-tier-of-world-producers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290618\" data-ts=\"1503317301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCAU\" target=\"_blank\">FCAU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290618-no-talks-yet-fiat-chrysler-and-great-wall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No talks yet between Fiat Chrysler and Great Wall</a></h4><ul> <li>Fiat Chrysler Automobiles (NYSE:<a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a>) says it hasn't been <a href=\"https://www.ft.com/content/eb9f122c-8653-11e7-bf50-e1c239b45787\" target=\"_blank\">approached</a> by Great Wall Motor (<a href='https://seekingalpha.com/symbol/GWLLY' title='Great Wall Motor Company, Ltd. ADR'>OTCPK:GWLLY</a>) about an acquisition.</li><li>The deal is seen by analysts as too large for Great Wall to absorb. While China Automotive Foresight analyst Yale Zhang doesn't think Great Wall has the financial capability to buy Fiat, he notes that Great Wall has a target to be the number one SUV maker in the world.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290563-great-wall-sets-sights-fca\" target=\"_blank\">Great Wall sets sights on FCA</a> (Aug. 21)</li>  <li>FCAU <font color='green'>+3.74%</font> premarket to $13.04.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3290618\" data-linked=\"No talks yet between Fiat Chrysler and Great Wall\" data-tweet=\"$FCAU $FCAU $GWLLY - No talks yet between Fiat Chrysler and Great Wall https://seekingalpha.com/news/3290618-no-talks-yet-fiat-chrysler-and-great-wall?source=tweet\" data-url=\"https://seekingalpha.com/news/3290618-no-talks-yet-fiat-chrysler-and-great-wall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290608\" data-ts=\"1503316415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290608-baml-raises-estimates-on-lululemon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML raises estimates on Lululemon</a></h4><ul> <li>Bank of America Merrill Lynch <a href=\"https://www.marketbeat.com/stocks/NASDAQ/LULU/\" target=\"_blank\">moves</a> Lululemon (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) to a Buy rating from Neutral on confidence in the retailer's international business.</li> <li>Analyst Rafe Jadrosich expects Lululemon same-store sales to rise 5% during the quarter. The estimate for 2017 EPS goes to $2.40 from $2.29 and 2018 EPS of $2.78 is seen vs. $2.58 prior view.</li> <li>The investment firm lifts its price target to $70 from $48.</li> <li>LULU <font color='green'>+2.06%</font> premarket to $59.33.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3290608\" data-linked=\"BAML raises estimates on Lululemon\" data-tweet=\"$LULU - BAML raises estimates on Lululemon https://seekingalpha.com/news/3290608-baml-raises-estimates-on-lululemon?source=tweet\" data-url=\"https://seekingalpha.com/news/3290608-baml-raises-estimates-on-lululemon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290597\" data-ts=\"1503315063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRV\" target=\"_blank\">CTRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290597-contravir-pharma-announces-issuance-of-new-us-patent-for-expansion-of-cyclophilin-inhibitor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraVir Pharma announces issuance of new US patent for expansion of Cyclophilin Inhibitor Program; shares ahead 12% premarket</a></h4><ul> <li>ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) <a href=\"https://seekingalpha.com/pr/16919554-contravir-pharmaceuticals-announces-issuance-new-us-patent-expansion-cyclophilin-inhibitor\" target=\"_blank\">announces</a> that the United States Patent and Trademark Office has issued a new patent, covering a broad collection of cyclophilin inhibitors. ContraVir currently has a lead cyclophilin inhibitor, <a href=\"https://contravir.com/crv431/\" target=\"_blank\">CRV431</a>, for use as an antiviral which is being developed for treatment of hepatitis B virus.</li><li>The Company anticipates that CRV431 will be used in conjunction with <a href=\"https://contravir.com/txl/\" target=\"_blank\">tenofovir exalidex</a> &#40;TXL&#41;, its lead drug currently in Phase 2 clinical trials.</li>   <li>The newly granted patent significantly extends the claims of the original CRV431 patent family.</li><li>Cyclophilins play a key role in many diverse diseases including infectious diseases, inflammation, cell death, muscular dystrophy, ischemia reperfusion, and oncogenesis.</li><li>Shares are up&nbsp;<font color='green'>12%</font>&nbsp;premarket on light volume.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3290597\" data-linked=\"ContraVir Pharma announces issuance of new US patent for expansion of Cyclophilin Inhibitor Program; shares ahead 12% premarket\" data-tweet=\"$CTRV $HEPA - ContraVir Pharma announces issuance of new US patent for expansion of Cyclophilin Inhibitor Program; shares ahead 12% premarket https://seekingalpha.com/news/3290597-contravir-pharma-announces-issuance-of-new-us-patent-for-expansion-of-cyclophilin-inhibitor?source=tweet\" data-url=\"https://seekingalpha.com/news/3290597-contravir-pharma-announces-issuance-of-new-us-patent-for-expansion-of-cyclophilin-inhibitor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3290598\" data-ts=\"1503314809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WUBA\" target=\"_blank\">WUBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3290598-58-com-beats-q2-guidance-estimates-shares-up-7_4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">58.com beats Q2, guidance estimates; shares up 7.4%</a></h4><ul><li>        58.com (NYSE:<a href='https://seekingalpha.com/symbol/WUBA' title='58.com Inc.'>WUBA</a>) reports Q2 results with EPS and revenue beats with sales up 33% on the year. Membership revenue was $142.3M, up 28% due to the 25% growth in the number of subscription-based paying membership accounts to about 2.5M. Online marketing services revenue up 37% to $226.8M.</li><li>               Cost of revenues was $34.7M, up 48% due primarily to an increase in traffic acquisition costs. R&amp;D costs were up 26% on the year because of increased hiring.&nbsp;</li><li>               Gross margin was 90.9% compared to 91.8% last year. Net cash from operating activities was $103.3M and the company ended the quarter with $550.4M in cash and equivalents. &nbsp;&nbsp;</li><li>               Q3 outlook puts revenue from $382M to $397M compared to the $351.05M consensus estimate.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16919501-58-com-reports-second-quarter-2017-unaudited-financial-results\" target=\"_blank\">Press release</a>&nbsp;</li><li>               58.com shares are&nbsp;<font color='green'>up 7.4%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290558-58-com-beats-0_46-beats-revenue\" target=\"_blank\">58.com beats by $0.46, beats on revenue</a> (Aug. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3290598\" data-linked=\"58.com beats Q2, guidance estimates; shares up 7.4%\" data-tweet=\"$WUBA - 58.com beats Q2, guidance estimates; shares up 7.4% https://seekingalpha.com/news/3290598-58-com-beats-q2-guidance-estimates-shares-up-7_4?source=tweet\" data-url=\"https://seekingalpha.com/news/3290598-58-com-beats-q2-guidance-estimates-shares-up-7_4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM </div></div></li>","count":48,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}